Employing D-Wave's annealing quantum computing solutions as accelerators in the speed and quality of training our generative AI-driven, drug discovery (DD) analysis systems, we constructed a hybrid quantum and classical computer system, aiming to extend the applicable range of molecular-generation AI systems in the DD field (i.e., AI-driven Drug Design). The goal of our project is to pioneer a new process for discovering 'first-in-class' pharmaceutical small compounds, which is performed with supports by D-Wave's team of professional services experts. In my talk, we report substantial aspects of our projects, based on the above-mentioned strategy and present progress.